AST Asterias Biotherapeutics, Inc.

3.18
0  -1%
Previous Close 3.20
Open 3.15
Price To book 3.43
Market Cap 147.62M
Shares 46,422,000
Volume 143,403
Short Ratio 7.93
Av. Daily Volume 183,830

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 2017.
AST-VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 2b planned for 2018.
AST-VAC1
Acute myeloid leukemia (AML)

Latest News

  1. 7:01 am Asterias Biotherapeutics reports that including the sixth and final patient in the AIS-A 10 million cell cohort in the co's ongoing SCiStar Phase 1/2a clinical trial has further confirmed previously-announced motor function improvem
  2. Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
  3. Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
  4. BioTime Reports $56M Non-Cash Gain On Deconsolidation
  5. Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
  6. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial Sta
  7. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
  8. Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
  9. Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
  10. Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
  11. Current report No 1/2017
  12. The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
  13. ETFs with exposure to Asterias Biotherapeutics, Inc. : December 27, 2016
  14. Is HC2 Holdings Inc (HCHC) A Good Stock To Buy?
  15. ETFs with exposure to Asterias Biotherapeutics, Inc. : December 8, 2016
  16. ETFs with exposure to Asterias Biotherapeutics, Inc. : November 28, 2016
  17. Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016
  18. ASTERIAS BIOTHERAPEUTICS, INC. Financials
  19. ASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
  20. Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics